Skip to main content
TOWA PHARMACEUTICAL CO.,LTD. logo

TOWA PHARMACEUTICAL CO.,LTD. — Investor Relations & Filings

Ticker · 4553 ISIN · JP3623150004 LEI · 35380036BH1C3PNO2426 T Manufacturing
Open in API
Filings indexed 69 across all filing types
Latest filing 2024-06-27 AGM Information
Country JP Japan
Listing T 4553

About TOWA PHARMACEUTICAL CO.,LTD.

https://www.towayakuhin.co.jp/english/

TOWA PHARMACEUTICAL CO.,LTD. is a pharmaceutical company specializing in the research, development, manufacturing, and marketing of generic drugs. Founded in 1951, the company is dedicated to providing high-quality and high added-value therapeutic solutions. Its product portfolio primarily consists of generic medications, which are distributed as ethical drugs, and also includes other products such as vitamins and antibiotics. The company focuses on the entire lifecycle of its pharmaceutical products, from initial development to final distribution, to meet various healthcare needs.

Recent filings

Filing Released Lang Actions
臨時報告書
AGM Information Classification · 100% confidence The document is titled "臨時報告書" (Extraordinary Report/Timely Disclosure Report) and is submitted to the Kinki Local Finance Bureau. The submission reason explicitly states that it is filed pursuant to Article 24-5, Paragraph 4 of the Financial Instruments and Exchange Act because resolutions were passed at the Annual General Meeting (AGM) held on June 25, 2024. The content details the results of voting on agenda items, including dividend approval and the election of directors. This structure—a formal report detailing the results of shareholder votes from a general meeting—perfectly matches the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA). Although it relates to the AGM, the core content is the voting outcome report, not the AGM presentation materials (AGM-R).
2024-06-27 Japanese
内部統制報告書－第68期(2023/04/01－2024/03/31)
Governance Information Classification · 100% confidence The document is explicitly titled "内部統制報告書" (Internal Control Report) in the header table. It references the legal basis as Article 24-4-4, Paragraph 1 of the Financial Instruments and Exchange Act (金融商品取引法), and the submission date is June 26, 2024, for the fiscal year ending March 31, 2024. This structure and content strongly indicate a formal report on the effectiveness of internal controls over financial reporting, which aligns with the requirements for an Audit Report/Information filing, especially since it is a standalone report focusing on internal controls rather than the full annual financial statements (10-K) or a general earnings release (ER). While 'AR' (Audit Report / Information) is the closest fit among the provided codes for a formal control assessment report, it is important to note that in the US context, this is often part of the 10-K. Given the Japanese context and the specific focus on internal control assessment ('内部統制報告書'), 'AR' is the most appropriate classification for a standalone audit/assessment report.
2024-06-26 Japanese
確認書
Regulatory Filings Classification · 100% confidence The document is titled '確認書' (Confirmation Letter) and explicitly references '金融商品取引法第24条の4の2第1項' (Article 24-4-2, Paragraph 1 of the Financial Instruments and Exchange Act). It serves as an officer certification confirming the accuracy of the company's Annual Securities Report (有価証券報告書). According to the 'CERTIFICATION RULE', documents that are primarily officer certifications or attestations should be classified as Regulatory Filings (RNS), even if they reference a specific report type. FY 2024
2024-06-26 Japanese
有価証券報告書－第68期(2023/04/01－2024/03/31)
Annual Report Classification · 100% confidence The document is a Japanese 'Yuuka Shouken Houkokusoku' (Annual Securities Report), which is the Japanese equivalent of a 10-K. It contains the standard cover page for such filings, identifying the company (Towa Pharmaceutical), the fiscal year (68th term, 2023-04-01 to 2024-03-31), and the regulatory submission to the Kinki Finance Bureau. It includes XBRL tags and detailed financial disclosure structures, confirming it is the full annual report rather than an announcement. FY 2024
2024-06-26 Japanese
確認書
Report Publication Announcement Classification · 100% confidence The document text contains the header "第３四半期報告書" (Third Quarter Report) and specifies a reporting period ("第68期第3四半期（自2023年10月1日 至2023年12月31日）"). It also references the Financial Instruments and Exchange Act ("金融商品取引法") and confirms the appropriateness of the filing's content by the CEO. This structure strongly indicates a comprehensive quarterly financial report, which aligns with the definition of an Interim / Quarterly Report (IR). The document length is very short (564 chars), but the content is the substance of the confirmation regarding the quarterly report itself, not merely an announcement of its publication. Therefore, IR is the most appropriate classification.
2024-02-14 Japanese
四半期報告書－第68期第3四半期(2023/10/01－2023/12/31)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) filed by Towa Pharmaceutical Co., Ltd. in accordance with the Financial Instruments and Exchange Act of Japan. It contains detailed financial statements, including the balance sheet, income statement, and comprehensive income statement for the third quarter of the fiscal year ending March 31, 2024. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). 9M 2024
2024-02-14 Japanese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.